Friday, 15 November 2019

ResTORbio's respiratory illness drug fails late-stage study

ResTORbio Inc's said on Friday its lead drug missed the main goal in a late-stage testing in patients aged above 65 with respiratory illness.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)